1. Type 1 Diabetes Caused by Interferon α-2α in Polycythemia Vera Therapy
- Author
-
Jingtao Dou, Zhao-Hui Lu, Juming Lu, Xian-ling Wang, Yi-Ming Mu, and Changyu Pan
- Subjects
Advanced and Specialized Nursing ,medicine.medical_specialty ,Type 1 diabetes ,business.industry ,Endocrinology, Diabetes and Metabolism ,medicine.disease ,Gastroenterology ,Polycythemia vera ,Male patient ,Interferon ,Internal medicine ,Diabetes mellitus ,Interferon α ,Immunology ,Internal Medicine ,Medicine ,Online Letters: Observations ,In patient ,business ,Viral hepatitis ,medicine.drug - Abstract
One of the main problems with long-term interferon α-2α (IFNα-2α) therapy for chronic viral hepatitis and malignant tumors is the development of autoimmune abnormalities. Up until now, there have been few reports about type 1 diabetes caused by IFNα-2α therapy in patients with polycythemia vera (PV) (1). A 59-year-old male patient without history of diabetes, whose fasting blood glucose (FBG) and A1C were 70.6 mg/dl and 4.8%, respectively, was diagnosed with PV in October 1999. He had been initially treated with Hydrea for 6 months, but the response had been unfavorable. Therefore, he switched to IFNα-2α (recombinant interferon α-2α; Shanghai Roche Pharmaceuticals, Shanghai, China) therapy, …
- Published
- 2010